NEW ORLEANS — In this video from the American Academy of Ophthalmology meeting, Dilraj Grewal, MD, highlights phase 2 and phase 3 data in age-related macular degeneration.
Grewal, of Duke Eye Center, also discussed subretinal and intravitreal delivery of gene therapy in neovascular AMD and potentially in geographic atrophy.
“We’re looking at promising data from gene therapy, promising data from new drugs like tyrosine kinase inhibitors, and we are getting closer to meeting the biggest need for our neovascular AMD patients, which is to extend the treatment interval and provide more consistent